Nafithromycin: India’s First Indigenous Antibiotic Launched

India has taken a significant step in addressing antimicrobial resistance (AMR) with the launch of its first indigenous antibiotic, Nafithromycin. Union Minister Dr. Jitendra Singh announced the launch of this innovative drug on November 20, 2024, in New Delhi.

What is Antibiotic Resistance?

Antibiotic resistance occurs when bacteria evolve to resist the effects of antibiotics, making infections harder to treat. Overuse and misuse of antibiotics in humans, animals, and agriculture accelerate this resistance, creating “superbugs” that render existing treatments ineffective.

The Global Challenge of Antibiotic Resistance

The world is grappling with a growing AMR crisis. It leads to longer hospital stays, higher medical costs, and increased mortality. Globally, AMR causes over 700,000 deaths annually, and this figure could rise to 10 million by 2050 without urgent action. Developing new antibiotics is essential, as very few drugs are currently in the pipeline.

Nafithromycin: A Breakthrough Solution

Developed with the support of the Biotechnology Industry Research Assistance Council (BIRAC), a unit under the Department of Biotechnology, Nafithromycin is marketed as “Miqnaf” by Wockhardt. This antibiotic is specifically designed to treat Community-Acquired Bacterial Pneumonia (CABP), which disproportionately affects children, the olders, and immunocompromised individuals.Dr. Singh described Nafithromycin as a game-changer, highlighting its ability to treat drug-resistant pneumonia. It offers ten times more efficacy than current options and requires only a three-day treatment regimen. Clinical trials have validated its superior safety, minimal side effects, and lack of food-related interactions.Notably, Nafithromycin is the first new antibiotic in its class globally in over three decades. It targets both typical and atypical pathogens, making it a robust solution against resistant bacteria.

India’s Role in Combating AMR

India bears 23% of the world’s pneumonia burden, making this innovation critical for public health. The development of Nafithromycin took 14 years and ₹500 crores, involving trials in India, the U.S., and Europe. This achievement showcases the success of public-private collaboration, with BIRAC supporting the initiative under its Biotechnology Industry Partnership Program (BIPP).Dr. Singh emphasized AMR as a global health threat, prolonging illnesses and raising healthcare costs. He urged stakeholders to strengthen efforts in diagnostics, AMR surveillance, and the development of new antibiotics.

A Milestone for India

The launch positions India as a global leader in biotechnology and pharmaceuticals. Nafithromycin’s soft launch aligns with World AMR Awareness Week, reinforcing the need for collective action to combat antibiotic resistance.Dr. Singh expressed optimism, calling the launch a milestone in India’s fight against AMR and a step toward a healthier future. Leaders from the scientific and healthcare communities hailed the event as a powerful example of India’s innovation and determination to tackle global health challenges.

Source: Press Information Bureau (PIB), Ministry of Science & Technology, Government of India.